Mercer Global Advisors’s Starling Oncology, Inc. Common Stock STLN Stock Holding History

Mercer Global Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39K	Buy	+256	New	+$1.07K	﹤0.01%	5673

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Mercer Global Advisors's STLN Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Starling Oncology, Inc. Common Stock (STLN) in Q2 2026: 256 shares worth $1.39K. The stake represents ﹤0.01% of the portfolio and ranks #5673 among its holdings.

83 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

Mercer Global Advisors held 256 shares of Starling Oncology, Inc. Common Stock worth $1.39K as of Q2 2026.
Starling Oncology, Inc. Common Stock was a new Mercer Global Advisors position in Q2 2026.
Starling Oncology, Inc. Common Stock made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5673 holding.
83 funds tracked by Wall St. Rank held Starling Oncology, Inc. Common Stock as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.